Q3 delivered 15% organic revenue growth, margin expansion, and strong cash flow, led by Endoscopy Solutions and price-driven gains in Anesthesia and Patient Monitoring. New product approvals and sustainability initiatives support future growth, with upgraded full-year guidance and ongoing investments in commercial and IT infrastructure.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.